Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ivabradine | Ivabradine may increase the QTc-prolonging activities of Carbinoxamine. |
| Buprenorphine | Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine. |
| Hydrocodone | Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Carbinoxamine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Carbinoxamine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine. |
| Mirtazapine | Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine. |
| Orphenadrine | Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine. |
| Pramipexole | Carbinoxamine may increase the sedative activities of Pramipexole. |
| Ropinirole | Carbinoxamine may increase the sedative activities of Ropinirole. |
| Rotigotine | Carbinoxamine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Carbinoxamine. |
| Sodium oxybate | Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine. |
| Thalidomide | Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Benzylpenicilloyl polylysine | Carbinoxamine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Carbinoxamine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Carbinoxamine. |
| Ethanol | Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fluvoxamine. |
| Duloxetine | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Sibutramine. |
| Zimelidine | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Alaproclate. |
| Nefazodone | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Nefazodone. |
| Amphetamine | Amphetamine may decrease the sedative activities of Carbinoxamine. |
| Phentermine | Phentermine may decrease the sedative activities of Carbinoxamine. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Carbinoxamine. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Carbinoxamine. |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of Carbinoxamine. |
| Mephentermine | Mephentermine may decrease the sedative activities of Carbinoxamine. |
| MMDA | MMDA may decrease the sedative activities of Carbinoxamine. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Carbinoxamine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Carbinoxamine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Carbinoxamine. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Carbinoxamine. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Carbinoxamine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Carbinoxamine. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Carbinoxamine. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Carbinoxamine. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Carbinoxamine. |
| Ritobegron | Ritobegron may decrease the sedative activities of Carbinoxamine. |
| Mephedrone | Mephedrone may decrease the sedative activities of Carbinoxamine. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Carbinoxamine. |
| Gepefrine | Gepefrine may decrease the sedative activities of Carbinoxamine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Carbinoxamine. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Carbinoxamine. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Carbinoxamine. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with Carbinoxamine. |
| Propiomazine | The risk or severity of CNS depression can be increased when Carbinoxamine is combined with Propiomazine. |
| Maprotiline | The risk or severity of CNS depression can be increased when Carbinoxamine is combined with Maprotiline. |
| Desipramine | The risk or severity of CNS depression can be increased when Carbinoxamine is combined with Desipramine. |
| Pizotifen | The risk or severity of CNS depression can be increased when Carbinoxamine is combined with Pizotifen. |
| Dosulepin | The risk or severity of CNS depression can be increased when Carbinoxamine is combined with Dosulepin. |
| Amitriptyline | The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Carbinoxamine. |
| Imipramine | The risk or severity of QTc prolongation can be increased when Imipramine is combined with Carbinoxamine. |
| Zopiclone | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Zopiclone. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Citalopram. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Anagrelide. |
| Disopyramide | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Disopyramide. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Clemastine. |
| Ibutilide | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Ibutilide. |
| Valproic acid | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Valproic acid. |
| Grepafloxacin | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Grepafloxacin. |
| Quinine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Quinine. |
| Sotalol | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Sotalol. |
| Toremifene | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Toremifene. |
| Imatinib | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Imatinib. |
| Thioridazine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Thioridazine. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Trovafloxacin. |
| Cocaine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Cocaine. |
| Procainamide | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Procainamide. |
| Arsenic trioxide | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Arsenic trioxide. |
| Escitalopram | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Escitalopram. |
| Domperidone | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Domperidone. |
| Sparfloxacin | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Sparfloxacin. |
| Halofantrine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Halofantrine. |
| Bepridil | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Bepridil. |
| Paliperidone | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Paliperidone. |
| Lithium cation | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Lithium cation. |
| Temafloxacin | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Temafloxacin. |